TechBio and Microbiome (III)
MetaphysicalCells: A newsletter about Science, Technology and AI Drug Discovery
👉🏼 TechBio and Microbiome (III),
TechBio and Microbiome (III)
🥁 Second Genome Inc
Second Genome has built a novel platform for microbiome drug discovery (peptides, proteins and small molecule) and has completed so far more than 400 microbiome studies, analyzing more than 75,000 samples, for internal R&D, as well as for external partners across government, academia, pharmaceutical, nutrition and industrial companies. The company applies AI in order to identify novel microbial biomarkers and develop precision therapies for conditions like inflammatory bowel disease (IBD) and metabolic disorders (Pipeline - Second Genome), and collaborates with pharmaceutical giants like Pfizer and Gilead Sciences.
More specifically, Second Genome leverages its microbiome analysis platform (Microbiome Discovery Platform) to uniquely addresses current limitations in target discovery and validation by:
Integrating computational science and ML with human disease biology to redefine diseases,
Building and maintaining structured databases of public and proprietary datasets, and by
Generating libraries of compounds that are screened in traditional drug discovery and development assays.
Built with innovative technologies, including ML analytics, customized protein engineering techniques, phage library screening, mass spec analysis and CRISPR, Second Genome’s platform enables researchers to identify genes and biomarkers, find bacterial proteins of interest and identify human drug targets. By coupling these insights with traditional drug development approaches, they are able to progress development of therapies and companion diagnostics for wide-ranging diseases.
Second Genome’s two Precision Therapeutics programs include 1️⃣ Immuno-oncology 🛡️, to turn immune checkpoint inhibitor non-responders to responders, and 2️⃣ Gastrointestinal Disorders 🚽🧻, to directly improve mucosal healing in gastrointestinal disorders.